Oncology Nursing Society (ONS)

The Oncology Nursing Society (ONS) is a professional association that represents 100,000 nurses and is the professional home to more than 35,000 members. ONS is committed to promoting excellence in oncology nursing and the transformation of cancer care. Since 1975, ONS has provided a professional community for oncology nurses, developed evidence-based education programs and treatment information, and advocated for patient care, all in an effort to improve the quality of life and outcomes for patients with cancer and their families.
New targets and innovative therapies for multiple myeloma were highlighted in two sessions presented at ONS 2023. Read More ›

Specific factors to be considered are outlined for the management of multiple myeloma treated with certain therapies. Read More ›

Common treatment-related adverse events and management approaches to multiple myeloma were outlined in three separate sessions at the ONS 2023 Congress. Read More ›

Approaches to help build healthcare professional and patient relationships and considerations for symptom management by patients with multiple myeloma are discussed. Read More ›

Healthcare disparities among Black and LGBTQ+ and gender minorities negatively impact clinical outcomes and survivorship. Read More ›

Chimeric antigen receptor T-cell therapy is an immunotherapeutic approach that has yielded favorable outcomes in various hematologic malignancies. Educating oncology nurses on how to recognize serious adverse events, such as cytokine release syndrome (CRS), is critical for early intervention and reducing CRS-related deaths. Read More ›

Breast cancer is the second leading cause of cancer-related deaths in women in the United States. Despite the increase in survival with trastuzumab in the adjuvant setting, up to 26% of patients with early-stage HER2+ breast cancer experience disease recurrence within 5 to 8 years. The interim analysis after 5 years of follow-up in the ExteNET trial is presented.

Read More ›

Adherence to prescribed therapy is pivotal in cancer treatment. To ensure that patients receive the full benefit of their prescribed therapy, nurses and nurse practitioners play a critical role in identifying adverse events and implementing effective interventions that balance efficacy and tolerability.

Read More ›

Nivolumab is an immune checkpoint inhibitor approved for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma. This immunotherapeutic agent is associated with immune-related adverse events that require prompt identification for successful management and resolution.

Read More ›

The use of monoclonal antibodies in the treatment of cancer is rapidly evolving. These immunomodulating agents are associated with an increased incidence of hypersensitivity reaction. Prompt identification and effective management is essential for optimal patient care.

Read More ›

Page 1 of 3